Epigenetic inactivation of ST6GAL1 in human bladder cancer

Abstract

BackgroundPosttranslational protein modifications are known to modulate key biological processes like proliferation and apoptosis. Accumulating evidence shows that ST6GAL1, an enzyme that catalyzes the transfer of sialic acid onto galactose-containing substrates, is aberrantly expressed in various cancers and may affect cell motility and invasion. This is the first study to describe ST6GAL1 expression and regulation in human bladder cancer.MethodsST6GAL1 mRNA expression levels in human cell lines (UROtsa, RT4, RT112 and J82) and tissue samples (n = 15 normal urothelium (NU), n = 13 papillary non-invasive tumors (pTa), n = 12 carcinoma in situ (CIS), n = 26 muscle invasive tumors (pT2-4)) were assessed using real-time PCR. In addition, ST6GAL1 protein expression was evaluated using immunohistochemistry. Promoter methylation analysis was performed using methylation-specific PCR (MSP) in cell lines (n = 4) and patient samples (n = 23 NU, n = 12 CIS, n = 29 pTa, n = 41 pT2-4). Epigenetic ST6GAL1 gene silencing was confirmed by in vitro demethylation of bladder cell lines. Data were validated by analysis of an independent bladder tumor data set (n = 184) based on The Cancer Genome Atlas (TCGA) portal.ResultsSemi-quantitative ST6GAL1 real-time PCR expression analysis showed two distinct trends: In muscle-invasive tumors ST6GAL1 expression was downregulation by 2.7-fold, while papillary non-invasive tumors showed an increased ST6GAL1 mRNA expression compared to normal urothelium. ST6GAL1 loss in muscle-invasive tumors was associated with increasing invasiveness. On the protein level, 69.2% (n = 45/65) of all tumors showed a weak ST6GAL1 protein staining (IRS ≤ 4) while 25.6% (16/65) exhibited a complete loss (IRS = 0) of ST6GAL1 protein. Tumor-specific DNA methylation of the ST6GAL1 promoter region was frequently found in pT2-4 tumors (53.6% (22/41)), whereas only 13.8% (4/29) of pTa tumors showed ST6GAL1 promoter methylation. Normal urothelium remained unmethylated. Importantly, we significantly revealed an inverse correlation between ST6GAL1 mRNA expression and ST6GAL1 promoter merthylation in primary bladder cancer. These findings were clearly verified by the TCGA public data set and in vitro demethylation assays functionally confirmed ST6GAL1 promoter methylation as a potential regulatory factor for ST6GAL1 gene silencing.ConclusionsOur study characterizes for the first time ST6GAL1 expression loss caused by aberrant ST6GAL1 promoter methylation potentially indicating a tumor suppressive role in bladder carcinogenesis.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2407-14-901) contains supplementary material, which is available to authorized users.

Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells

“…Absorbance (A 490 ) was measured at 490 nm on an enzyme-linked immunosorbent assay plate reader. The inhibition rate was calculated using the following formula: cell proliferation inhibition rate = (the average of A 490 values from the control group - the average of A 490 values from the experimental group)/the average of A 490 values from the control group × 100% [22]. All experiments were performed in triplicate and more than three wells were used for each treatment.…”

“…A complete medium containing 800 μg/ml G418 was added, and stably expressed transfected cells were obtained by being screened for 2 weeks. Strains were acquired by expanded culture and stored in liquid nitrogen prior to further analysis [22]. …”

“…The final score was determined by adding the intensity of positive staining and the percentage of positive cells, yielding a range from 0 to 7. The expression of ST6Gal-I and BCL-2 was considered positive when the scores were ≥2; 2 to 3 was considered weak; 4 to 5 was considered moderate; and 6 to 7 was considered strong [22, 24]. …”

Multi-level regulation of cellular glycosylation: from genes to transcript to enzyme to structure

“…This is even less studied than transcription factor binding to glycogenes, although a recent study analyzing DNA methylation of 86 glycogenes suggests a positive correlation between the promoter methylation status of glycogenes and expected tumor-associated glycan structures [17]. A handful of studies have also shown a direct interaction between the methylation status of specific glycogenes and glycogene expression [18–21]. In this regard, the methylation of the α(2,3)sialyltransferase ST6Gal1 promoter was shown to silence expression of the ST6Gal1 transcript in bladder cancer [18], confirming an earlier report in breast cancer showing methylation-dependent silencing of this glycogene [22].…”

Glycosylation is a global target for androgen control in prostate cancer cells

“…Expression reduced by epigenetic inactivation in bladder cancer (Antony et al 2014). Linked to EMT transition and malignancy (Lu et al 2014) Androgen regulated and linked to prostate cancer cell viability B4GALT1 Late processing of N-glycans (transfers a galactose residue to terminal N-acetylglucosamine)…”